TY - JOUR
T1 - Advancing pharmacy and healthcare with virtual digital technologies
AU - Trenfield, Sarah J.
AU - Awad, Atheer
AU - McCoubrey, Laura E.
AU - Elbadawi, Moe
AU - Goyanes, Alvaro
AU - Gaisford, Simon
AU - Basit, Abdul W.
N1 - Funding Information:
The authors thank the Engineering and Physical Sciences Research Council (EPSRC), UK for their financial support (EP/S023054/1 and EP/S009000/1). Fig. 6 and the graphical abstract were created using BioRender.com.
Funding Information:
The authors thank the Engineering and Physical Sciences Research Council (EPSRC), UK for their financial support (EP/S023054/1 and EP/S009000/1). Fig. 6 and the graphical abstract were created using BioRender.com. Prof Abdul W. Basit, Prof Simon Gaisford and Dr Alvaro Goyanes are co-founders of FabRx Ltd, Canterbury, UK. ihttps://ec.europa.eu/newsroom/dae/items/709090.
Publisher Copyright:
© 2021
PY - 2022/3
Y1 - 2022/3
N2 - Digitalisation of the healthcare sector promises to revolutionise patient healthcare globally. From the different technologies, virtual tools including artificial intelligence, blockchain, virtual, and augmented reality, to name but a few, are providing significant benefits to patients and the pharmaceutical sector alike, ranging from improving access to clinicians and medicines, as well as improving real-time diagnoses and treatments. Indeed, it is envisioned that such technologies will communicate together in real-time, as well as with their physical counterparts, to create a large-scale, cyber healthcare system. Despite the significant benefits that virtual-based digital health technologies can bring to patient care, a number of challenges still remain, ranging from data security to acceptance within the healthcare sector. This review provides a timely account of the benefits and challenges of virtual health interventions, as well an outlook on how such technologies can be transitioned from research-focused towards real-world healthcare and pharmaceutical applications to transform treatment pathways for patients worldwide.
AB - Digitalisation of the healthcare sector promises to revolutionise patient healthcare globally. From the different technologies, virtual tools including artificial intelligence, blockchain, virtual, and augmented reality, to name but a few, are providing significant benefits to patients and the pharmaceutical sector alike, ranging from improving access to clinicians and medicines, as well as improving real-time diagnoses and treatments. Indeed, it is envisioned that such technologies will communicate together in real-time, as well as with their physical counterparts, to create a large-scale, cyber healthcare system. Despite the significant benefits that virtual-based digital health technologies can bring to patient care, a number of challenges still remain, ranging from data security to acceptance within the healthcare sector. This review provides a timely account of the benefits and challenges of virtual health interventions, as well an outlook on how such technologies can be transitioned from research-focused towards real-world healthcare and pharmaceutical applications to transform treatment pathways for patients worldwide.
KW - Computational drug discovery and development
KW - Cybermedicine
KW - Digital and virtual twinning
KW - Digitised drug delivery
KW - Electronic health (e-health)
KW - Industry X.0
KW - On-demand drug manufacturing
KW - Pharmacy or Pharma 4.0
KW - Precision and personalized medicine
KW - Telecommunication
UR - http://www.scopus.com/inward/record.url?scp=85123188623&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.114098
DO - 10.1016/j.addr.2021.114098
M3 - Review article
C2 - 34998901
AN - SCOPUS:85123188623
SN - 0169-409X
VL - 182
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
M1 - 114098
ER -